<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00107523</url>
  </required_header>
  <id_info>
    <org_study_id>1945.00</org_study_id>
    <secondary_id>FHCRC-1945.00</secondary_id>
    <secondary_id>MDA-2004-0185</secondary_id>
    <secondary_id>CDR0000419678</secondary_id>
    <nct_id>NCT00107523</nct_id>
  </id_info>
  <brief_title>Pravastatin, Idarubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia</brief_title>
  <official_title>A Phase I Trial Evaluating the Effect of the Addition of HMGCoA-Reductase Inhibition With Pravastatin to Salvage Chemotherapy Idarubicin-HDAC in Patients With Relapsed or Refractory Acute Myelogenous Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as idarubicin and cytarabine, work in different&#xD;
      ways to stop the growth of cancer cells, either by killing the cells or by stopping them from&#xD;
      dividing. Pravastatin may help idarubicin and cytarabine work better by making cancer cells&#xD;
      more sensitive to the drugs. Giving pravastatin together with idarubicin and cytarabine may&#xD;
      kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of pravastatin when&#xD;
      given together with idarubicin and cytarabine in treating patients with acute myeloid&#xD;
      leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the biological efficacy of pravastatin in leukemia cells, in terms of&#xD;
           measuring surrogate endpoints, including cellular cholesterol, messenger RNA encoding&#xD;
           cholesterol synthesis, cholesterol import regulators, and specific protein&#xD;
           farnesylation, in patients with acute myeloid leukemia.&#xD;
&#xD;
        -  Determine whether increasing doses of pravastatin, when administered with idarubicin and&#xD;
           high-dose cytarabine, produce increased apoptosis in leukemia cells of these patients.&#xD;
&#xD;
        -  Determine the maximum tolerated dose (MTD) of pravastatin when administered with&#xD;
           idarubicin and high-dose cytarabine in these patients.&#xD;
&#xD;
        -  Determine whether the MTD of pravastatin is required to achieve the maximal biological&#xD;
           effect on cholesterol metabolism in leukemia cells of these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, multicenter, dose-escalation study of pravastatin.&#xD;
&#xD;
      Patients receive oral pravastatin once daily on days 1-8, idarubicin IV over 30 minutes on&#xD;
      days 4-6, and high-dose cytarabine IV continuously on days 4-7. Treatment repeats every 28-42&#xD;
      days for up to 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
      Patients achieving a complete remission (CR) may receive additional treatment with the same&#xD;
      doses of study drugs over fewer days. These patients receive oral pravastatin once daily on&#xD;
      days 1-6 and idarubicin IV over 30 minutes and high-dose cytarabine IV continuously on days 4&#xD;
      and 5. Patients experiencing disease response with severe side effects may receive additional&#xD;
      treatment at a lower dose of the study drug causing the side effects.&#xD;
&#xD;
      Cohorts of 3 patients receive escalating doses of pravastatin until the maximum tolerated&#xD;
      dose (MTD)* is determined or a predetermined maximum dose is reached.&#xD;
&#xD;
      NOTE: *Patients achieving a CR with a dose of pravastatin that is subsequently determined to&#xD;
      be above the MTD receive pravastatin at the MTD for all subsequent courses.&#xD;
&#xD;
      After completion of study treatment, patients are followed at least every 3 months for 2&#xD;
      years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 36 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">October 2005</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biological efficacy by measuring surrogate end-points, including cellular cholesterol, messenger RNAs encoding cholesterol synthesis and cholesterol import regulators, and specific protein farnesylation</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Leukemia cell apoptosis</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of pravastatin</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximal biological effect on cholesterol metabolism achieved with or without the MTD of pravastatin</measure>
  </primary_outcome>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>idarubicin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pravastatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of acute myeloid leukemia (AML) meeting 1 of the following criteria:&#xD;
&#xD;
               -  Newly diagnosed disease (MDACC patients only)&#xD;
&#xD;
               -  In first or second relapse AND scheduled to receive first salvage therapy&#xD;
&#xD;
               -  Primary refractory disease after prior induction therapy for newly diagnosed&#xD;
                  disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Zubrod 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST or ALT ≤ 2 times normal&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2 times normal&#xD;
&#xD;
          -  Bilirubin &lt; 2.0 mg/dL&#xD;
&#xD;
          -  No acute or chronic hepatic impairment&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine &lt; 1.5 times normal (unless secondary to acute myeloid leukemia)&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Ejection fraction (EF) ≥ 45% by MUGA or 2-D echocardiogram&#xD;
&#xD;
               -  Patients who have an EF &lt; 45% OR cardiac symptoms must be evaluated and cleared&#xD;
                  by cardiology to be eligible for study entry&#xD;
&#xD;
          -  No cardiac contraindication to idarubicin&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No uncontrolled or life threatening infection&#xD;
&#xD;
          -  No known intolerance to study drugs&#xD;
&#xD;
          -  Must be able to safely tolerate the 3-day delay between the start of pravastatin and&#xD;
             the start of chemotherapy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other concurrent HMG-CoAR inhibitors, including any of the following:&#xD;
&#xD;
               -  Atorvastatin&#xD;
&#xD;
               -  Fluvastatin&#xD;
&#xD;
               -  Lovastatin&#xD;
&#xD;
               -  Rosuvastatin&#xD;
&#xD;
               -  Simvastatin&#xD;
&#xD;
          -  No concurrent non-HMG-CoAR inhibitors to lower cholesterol&#xD;
&#xD;
          -  No concurrent use of any of the following medications:&#xD;
&#xD;
               -  Bezafibrate&#xD;
&#xD;
               -  Clofibrate&#xD;
&#xD;
               -  Fenofibrate&#xD;
&#xD;
               -  Gemfibrozil&#xD;
&#xD;
               -  Cholestipol&#xD;
&#xD;
               -  Cholestyramine resin&#xD;
&#xD;
               -  Colesevelam&#xD;
&#xD;
               -  Ezetimibe&#xD;
&#xD;
               -  Biphenabid&#xD;
&#xD;
               -  Niacin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen H. Petersdorf, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center at University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>April 5, 2005</study_first_submitted>
  <study_first_submitted_qc>April 5, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2005</study_first_posted>
  <last_update_submitted>September 20, 2010</last_update_submitted>
  <last_update_submitted_qc>September 20, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2010</last_update_posted>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Pravastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

